This brand name is authorized in Finland, France, Netherlands.
The drug WILFACTIN contains one active pharmaceutical ingredient (API):
1
|
UNII
ZE22NE22F1 - VON WILLEBRAND FACTOR HUMAN
|
|
Administration of von Willebrand factor allows correction of the haemostatic abnormalities exhibited by patients who suffer from von Willebrand factor deficiency. |
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| B02BD10 | Von Willebrand factor | B Blood and blood forming organs → B02 Antihemorrhagics → B02B Vitamin K and other hemostatics → B02BD Blood coagulation factors |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| FI | Lääkealan turvallisuus- ja kehittämiskeskus | 073233 |
| FR | Base de données publique des médicaments | 67624035 |
| NL | Z-Index G-Standaard | 15602427 |
| NL | Z-Index G-Standaard, PRK | 94153 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.